The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | ESMO 2018 Congress
Colorectal Cancer Case Studies

Tanios Bekaii-Saab, MD: Percentage of RAS Mutation Tests in Metastatic CRC

Tanios Bekaii-Saab, MD
Published Online:Apr 26, 2016
Case 2 examines a 52-year-old woman newly diagnosed with metastatic CRC who is genotyped as part of her initial work up.

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 1
Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2
Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 1
Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2


What are the data on the percentage of patients with metastatic CRC who currently are tested for RAS mutations? 

In the United States, it's about 50% of 70% of all physicians for tests with RAS mutations before initiating treatment. This number should be 100%, but there are a number of limitations as to why it's not 100% at this point.

Unresectable Colon Cancer: Case 2

52-year-old woman newly diagnosed with metastatic CRC and is genotyped as part of her initial work up.

Publications
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.